



Date: 15-05-2026

National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex,  
Bandra East, Mumbai-400051  
Scrip Code: MUKKA

BSE Limited  
Listing Department  
Dalal Street,  
Mumbai-400001  
Scrip Code: 544135

Dear Sir/Madam,

**Subject: Outcome of the Board Meeting held on 15th May 2026.**

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force), this is to inform you that the Board of Directors of the Company ("Board") at their meeting held today i.e. 15th May 2026, have *inter-alia* approved the following business:

- Financial Results:** The audited financial results (standalone and consolidated) of the Company for the quarter and year ended 31st March 2026. The same is enclosed. Further, the Independent Auditor's Report received from the Statutory Auditors and a declaration by the Chief Financial Officer of the Company with respect to unmodified opinion on the said audited financial results are enclosed herewith.
- Fund raising:** The Board approved raising of funds by way of proposed issuance of certain secured, rated, listed, redeemable, non-convertible debentures of the aggregate nominal value of up to 25,00,00,000/- (Rupees Twenty-Five Crores only) on a private placement basis via Electronic Bidding Platform (EBP) on the terms and conditions as may be decided by the Board from time to time.
- Fund raising:** The Board has approved raising of funds by way of proposed issuance of certain secured, rated, listed, non-convertible debentures of the aggregate nominal value of up to Rs. 50,00,00,000/- (Rupees Fifty Crores only) on a private placement basis in one or more tranches/series via Electronic Bidding Platform (EBP) or non EBP over a period of time on the terms and conditions as may be decided by the Board from time to time.
- To invest in MPL FC HRC JV:** The Board has approved to make investment in a partnership firm proposed to be constituted under the name "MPL FC HRC JV" or such other name as may be mutually agreed by the partners and to make a capital contribution of ₹2,55,000 (Rupees Two Lakh Fifty-Five Thousand only) representing 51% profit sharing in the partnership firm.
- To incorporate and invest in an overseas entity:** The Board has approved to incorporate and invest in an overseas entity in Sri Lanka under the name and style "Lanka Bio Proteins Private Limited" or such other name as may be approved by the relevant authorities in Sri Lanka. The Company proposes to invest in and subscribe to the share capital for an amount not exceeding

**Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste**



# Mukka Proteins Limited



ISO 22000  
Certified Company



ISO 9001 : 2015  
Certified Company

Rs. 2,50,00,000/- (Rupees Two Crores Fifty Lakhs Only) equivalent to 9,75,00,000 Sri Lankan Rupee (Sri Lankan Rupees Nine Crore Seventy-Five Lakhs only) approx. representing **49%** of the share capital of the proposed entity.

The detailed disclosure as required under SEBI Circular No. SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123 dated July 13, 2023 and such other circulars as applicable, in respect of point no. 2, 3, 4 and 5 is enclosed as Annexure I, II, III and IV respectively.

The Meeting commenced at 03:20 p.m. and concluded at 3:55 p.m.

This is for your information and records.

Thank you,  
For **Mukka Proteins Limited**

**Mehaboobsab Mahmados Chalyal**  
**Company Secretary & Compliance Officer**  
**Membership No.: A67502**

Encl: as above.

## Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste

**Factory** : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India  
**Office** : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001  
☎ : (0) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405  
E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771

**Independent Auditor's Report on the Audit of the Standalone Financial Results for the quarter and year ended on 31<sup>st</sup> March, 2026, of Mukka Proteins Limited pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**TO THE BOARD OF DIRECTORS OF MUKKA PROTEINS LIMITED**

**Report on the Audit of Standalone Financial Results**

**Opinion**

We have audited the accompanying Statement of Standalone Financial Results of **MUKKA PROTEINS LIMITED** (the "Company"), for the quarter and year ended March 31, 2026, (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- a) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, and
- b) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) prescribed and other accounting principles generally accepted in India of the net profit and other comprehensive income, and other financial information of the Company for the quarter and year ended March 31, 2026

**Basis for Opinion**

We conducted our audit of the Statement in accordance with the Standards on Auditing ("SA") specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financials Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the quarter and year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

**Management's Responsibilities for the Standalone Financial Results**

The Statement, which includes the Standalone financial results is the responsibility of the Company's Board of Directors, and has been approved by it for the issuance. The Statement has been compiled from the related audited Standalone Financial Statements as at and for the year ended March 31, 2026. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Ind AS, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies, making judgments and estimates that are reasonable and prudent; and the design,



implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view, and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatement can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.



- Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to express an opinion on the Standalone Financial Results.

Materiality is the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Other Matter**

The Standalone financial results includes the results for the quarter ended 31<sup>st</sup> March, 2026 being the balancing figure between audited figures in respect of full financial year and the published year to date figures up to the third quarter of the current financial year, which were subject to limited review by us, as required under the Listing Regulations. Our opinion on the Audit of the Standalone Financial Results for the year ended 31<sup>st</sup> March, 2026 is not modified in respect of this matter.

**For SHAH & TAPARIA**

Chartered Accountants

FRN: 109463W



**Bharat Joshi**

Partner

M. No.: 130863

UDIN: 26130863 MVXRFT 2181

Date: May 15, 2026

Place: Mumbai

**MUKKA PROTEINS LIMITED**  
**CIN: L10207KA2010PLC055771**  
**STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE**  
**QUARTER & YEAR ENDED MARCH 31, 2026**

*(Rupees in million, except per share data and if otherwise stated)*

Sr. No.	Particulars	Quarter Ended			Year ended	
		March 31, 2026	December 31,2025	March 31, 2025	March 31, 2026	March 31, 2025
		(Audited)	(Un-Audited)	(Audited)	(Audited)	(Audited)
<b>1</b>	<b>Revenue from operations</b>					
	Revenue from operations	3,002.56	5,387.53	3,159.89	11,849.54	8,603.53
	Other operating income	126.21	195.11	93.09	442.51	263.90
	<b>Total Revenue from operations</b>	<b>3,128.77</b>	<b>5,582.64</b>	<b>3,252.98</b>	<b>12,292.05</b>	<b>8,867.43</b>
2	Other income	137.93	71.71	40.58	292.68	166.51
3	<b>Total income (1+2)</b>	<b>3,266.70</b>	<b>5,654.35</b>	<b>3,293.56</b>	<b>12,584.73</b>	<b>9,033.94</b>
4	<b>Expenses</b>					
	Cost of Material Consumed	3,152.80	5,230.77	2,308.53	12,644.41	8,197.35
	Changes in inventories of finished goods, stock in trade and work in progress	(666.05)	(434.32)	356.21	(2535.76)	(1271.59)
	Employee benefits expenses	62.41	70.99	55.72	245.13	216.40
	Finance costs	137.44	137.33	89.12	499.10	343.26
	Depreciation and amortisation expenses	25.60	15.26	13.56	69.39	58.61
	Other expenses	288.43	388.63	299.86	1,074.66	964.12
	<b>Total expenses</b>	<b>3,000.63</b>	<b>5,408.68</b>	<b>3,123.00</b>	<b>11,996.94</b>	<b>8,508.14</b>
5	<b>Profit before exceptional item and tax (3-4)</b>	<b>266.07</b>	<b>245.68</b>	<b>170.56</b>	<b>587.79</b>	<b>525.81</b>
6	<b>Exceptional items</b>	-	-	-	-	-
7	<b>Profit before tax (5-6)</b>	<b>266.07</b>	<b>245.68</b>	<b>170.56</b>	<b>587.79</b>	<b>525.81</b>
8	<b>Total tax expenses</b>					
	Current Tax	88.67	56.41	43.44	171.68	98.49
	Deferred Tax	(19.98)	1.68	(7.20)	(16.29)	(0.83)
	Earlier years	8.28	0.00	3.44	8.28	11.31
9	<b>Profit after tax (7+8-9)</b>	<b>189.09</b>	<b>187.59</b>	<b>130.89</b>	<b>424.12</b>	<b>416.83</b>
10	<b>Other Comprehensive Income/ (Expenses) (net of tax)</b>					
	<u>Items that will not be reclassified to profit or loss</u>					
	-Remeasurements of the defined benefit plans	2.08	1.90	(1.21)	5.19	0.38
11	<b>Other comprehensive income, net of tax</b>	<b>2.08</b>	<b>1.90</b>	<b>(1.21)</b>	<b>5.19</b>	<b>0.38</b>
12	<b>Total Comprehensive Income for the Period (after tax) (10+11)</b>	<b>191.18</b>	<b>189.48</b>	<b>129.68</b>	<b>429.32</b>	<b>417.21</b>
13	<b>Paid-up equity share capital (Face Value of the share Rs. 1/- each)</b>	300.00	300.00	300.00	300.00	300.00
14	Other equity	-	-	-	4,172.98	3,743.66
15	<b>Earnings per share * (Face Value Rs. 1/- per share)</b>					
	(a) Basic	0.64	0.63	0.43	1.43	1.39
	(b) Diluted	0.64	0.63	0.43	1.43	1.39

\*\* Basic & Diluted EPS for all periods , except year ended March 31, 2026 & March 31, 2025, are not annualised.  
See accompanying notes to the financial results

**MUKKA PROTEINS LIMITED**  
**CIN: L10207KA2010PLC055771**  
**AUDITED STANDALONE BALANCE SHEET AS AT MARCH 31, 2026**

*(Rupees in million, except per share data and if otherwise stated)*

Particulars	As at	As at
	March 31, 2026	March 31, 2025
	Rs. In millions	Rs. In millions
<b>ASSETS</b>		
<b>Non-Current assets</b>		
Property, Plant and Equipment	751.77	559.22
Capital Work in Progress	3.70	38.03
Right-of-use Assets	117.61	22.47
Intangible Assets	1.63	0.68
Intangible Assets under development	1.65	0.00
Investment Property	12.19	12.60
Financial Assets		
Investment	710.34	438.04
Loans	0.00	0.00
Other Financial Asset	184.70	13.48
Income Tax Assets	54.89	20.40
Other non-current assets	242.97	70.80
<b>Total Non-Current Assets</b>	<b>2,081.44</b>	<b>1,175.72</b>
<b>Current assets</b>		
Inventories	7,741.35	5,205.58
Financial Assets		
Trade Receivables	1,738.35	1,550.13
Cash and Cash Equivalents	19.41	4.43
Other bank balances	461.20	387.64
Loans	135.15	131.76
Other Financial Assets	160.11	201.01
Other Current Assets	1,346.89	1,083.68
<b>Total Current Assets</b>	<b>11,602.45</b>	<b>8,564.23</b>
<b>Total Assets</b>	<b>13,683.89</b>	<b>9,739.95</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity Share Capital	300.00	300.00
Other Equity	4,172.98	3,743.66
<b>Total Equity</b>	<b>4,472.98</b>	<b>4,043.66</b>
<b>LIABILITIES</b>		
<b>Non-Current Liabilities</b>		
Financial Liabilities		
Borrowings	60.74	12.87
Lease Liabilities	109.88	16.19
Other Financial Liabilities	-	-
Provisions	23.77	22.31
Deferred Tax Liabilities (Net)	8.88	25.14
Other Non-Current Liabilities	1.53	1.91
<b>Total Non-Current Liabilities</b>	<b>204.81</b>	<b>78.42</b>
<b>Current Liabilities</b>		
Financial Liabilities		
Borrowings	6,639.13	4,138.00
Lease Liabilities	13.71	10.04
Trade Payables		
- Due to Micro & Small Enterprises	697.83	321.29
- Due to other than Micro & Small Enterprises	1,381.75	996.71
Other Financial Liabilities	37.25	29.41
Other Current Liabilities	54.90	25.72
Provisions	9.85	13.12
Income Tax Liabilities	171.68	83.57
<b>Total Current Liabilities</b>	<b>9,006.10</b>	<b>5,617.86</b>
<b>Total Equity and Liabilities</b>	<b>13,683.89</b>	<b>9,739.95</b>

**MUKKA PROTEINS LIMITED**  
**CIN: L10207KA2010PLC055771**  
**AUDITED STANDALONE CASH FLOW STATEMENT FOR THE QUARTER AND**  
**YEAR ENDED MARCH 31, 2026**

*(Rupees in million, except per share data and if otherwise stated)*

Particulars	Year Ended 31st March 2026	Year Ended 31st March 2025
	Rs. In millions	Rs. In millions
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit before tax	587.79	525.81
Adjustment for :		
Depreciation / Amortization	69.39	58.61
Interest Expenses	492.55	234.12
Interest Expenses on Lease Liability & Security Deposits	6.56	2.84
Interest on Capital & Remuneration from partnership firm	(12.69)	(23.40)
Rent Received	(18.43)	(17.62)
Deferred Subsidy	(0.38)	(0.38)
Interest Income	(42.69)	(30.20)
(Profit)/loss on Sale of Fixed Assets	(0.64)	0.23
Gain on Termination of lease contract	(0.07)	-
	<b>493.58</b>	<b>224.19</b>
<b>Operating profit before working capital changes</b>	<b>1,081.37</b>	<b>750.00</b>
Adjustment for :		
Inventories	(2535.76)	(1271.59)
Trade Receivables and Other Assets	(830.86)	(670.36)
Trade Payables	761.59	61.24
Other Current & Non Current Liabilities	29.18	22.46
Provisions	3.38	9.21
Other Financial liabilities	7.84	(198.47)
Other Non-Current Liabilities	(0.38)	-
	<b>(2565.02)</b>	<b>(2047.51)</b>
<b>Net Cash Generated from Operating activity</b>	<b>(1483.65)</b>	<b>(1297.51)</b>
Income Tax Paid	(126.30)	(26.24)
<b>Net Cash from operating activities</b>	<b>(1609.95)</b>	<b>(1323.75)</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of fixed assets	(265.05)	(55.80)
Investment in Capital Works-in-Progress	34.33	(38.03)
Sale proceeds from FA	1.54	1.10
Interest received	42.69	30.20
Investment Property Changes	0.41	-
Interest on Capital & Remuneration Received from Partnership Firm	12.69	23.40
Rent Received	18.43	17.62
Net (Increase) / Decrease in Investments	(272.30)	(158.64)
<b>Net cash used in investing activities</b>	<b>(427.26)</b>	<b>(180.16)</b>
<b>C. CASH FLOW FROM FINANCIAL ACTIVITIES</b>		
Net Proceeds from Issue (Net of Share Issue Expenses)	-	(25.27)
Changes in borrowings - Non Current	47.87	(20.31)
Interest Paid	(492.55)	(234.12)
Changes in borrowings - Current	2,501.13	892.84
Repayment of Lease Liabilities	(4.27)	(16.63)
<b>Net Cash from financial activities</b>	<b>2,052.19</b>	<b>596.51</b>
<b>INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>14.98</b>	<b>(907.40)</b>
Cash and Cash equivalents at the beginning	4.43	911.83
Cash and Cash equivalents at the close	<b>19.41</b>	<b>4.43</b>

**MUKKA PROTEINS LIMITED**  
**CIN: L10207KA2010PLC055771**  
**NOTES TO THE STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE**  
**QUARTER & YEAR ENDED MARCH 31, 2026**

- 1 The above statement of Audited standalone financial results for the Quarter & Year ended March 31, 2026 ('the Statement') of Mukka Proteins Limited ('the Company') are reviewed and recommended by the Audit Committee and taken on record by the Board of Directors at their meeting held on **May 15, 2026**. The Statutory auditors have carried out an audit of the standalone financial results for the Quarter & Year ended March 31, 2026 and have issued an unmodified opinion on the same.
- 2 The Audited Standalone Financial Results of the company are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard Rules), 2015 (as amended) and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended.
- 3 The figures for the quarter ended March 31, 2026 are balancing figure between the audited figures for the year ended March 31, 2026 and published year to date figures for nine months ended December 31, 2025.

The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures for the year ended March 31, 2025 and unaudited figures for the nine months period ended December 31, 2024.

- 4 The Group operates in a single operating segment namely Fish & Insects Protein. The Board of directors is the Chief Operating Decision Maker (the "CODM") of the group and makes operating decisions, assess financials performance & allocate resources based upon discrete financial information. Since the Company operate in a single operating segment, separate segment reporting has not been made under Indian Accounting Standard ("Ind AS") 108 - "Operating Segment". Further, the operation of the Group comprises of geographical segment as disclosed below -

Revenue disaggregation by geography is as follows :-

*(Rupees in Million)*

Particulars	Quarter Ended			Year ended	
	March 31, 2026	December 31, 2025	March 31, 2025	March 31, 2026	March 31, 2025
	(Audited)	(Un-Audited)	(Audited)	(Audited)	(Audited)
Within India	167.52	1,210.85	1,241.14	2,406.66	3,034.56
Outside India	2835.05	4,176.69	1,918.75	9,442.88	5,568.97
<b>Total</b>	<b>3,002.56</b>	<b>5,387.53</b>	<b>3,159.89</b>	<b>11,849.54</b>	<b>8,603.53</b>

- 5 The figures for comparative period have been regrouped/ reclassified, wherever necessary, to make them comparable.

**For and on behalf of Board of Directors of**  
**Mukka Proteins Limited**

Date - May 15, 2026  
Place: Mangalore

**Kalandan Mohammed Haris**  
Managing Director and CEO  
DIN: 03020471

**Independent Auditor's Report on the Audit of the Consolidated Financial Results for the quarter and year ended 31<sup>st</sup> March, 2026 of Mukka Proteins Limited pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**TO THE BOARD OF DIRECTORS OF MUKKA PROTEINS LIMITED**

**Report on the Audit of Consolidated Financial Results**

**Opinion**

We have audited the accompanying Statement of Consolidated Financial Results of **MUKKA PROTEINS LIMITED** (the "Company"), its subsidiaries (the Company and its subsidiaries together referred to as the "Group") and its associates and joint ventures for the quarter and year ended March 31, 2026, (the "Statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on financial statements / financial results / financial information of subsidiaries, associates and joint ventures referred to in Other Matters section below, the Statement:

- i. includes the results of the entities as mentioned in Annexure 1 below;
- ii. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
- iii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group for the quarter and year ended March 31, 2026.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those SAs are further described in the "Auditor's Responsibilities for Audit of the Consolidated Financial Results" section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

**Management's Responsibilities for the Consolidated Financial Results**

The Statement which includes Consolidated Financial Results is the responsibility of the Company's Board of Directors and has been approved by it for the issuance. The Statement has been compiled from the audited Consolidated Financial Statements as at and for the year ended March 31, 2026. This responsibility includes the preparation and presentation of the Consolidated Financial Results that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group in accordance with the applicable accounting standards prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting



principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Boards of Directors of entities included in the Group are responsible for maintenance of the adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies, making judgments and estimates that are reasonable and prudent, and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Financial Results by the Directors of the Company, as aforesaid.

In preparing the Consolidated Financial Results, the respective Boards of Directors of the entities included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Boards of Directors either intend to liquidate their respective entities or to cease operations, or have no realistic alternative but to do so.

The respective Boards of Directors of entities included in the Group are responsible for overseeing the financial reporting process of the Group.

#### **Auditor's Responsibilities for Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of those Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.



- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group to cease to continue at a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Results, including the disclosures, and whether the Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial Information/ Financial Results of the entities within the group and its associates and joint ventures to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Consolidated Financial Results of which we are the independent auditors. For the other entities included in the statement, which have been audited by the other auditors, such auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Results.


We communicate with those charged with governance of the Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

#### **Other Matter**

1. Consolidated Financial Results includes the audited Financial Results of eight subsidiaries, whose financial statements / financial information reflects Group's Share of total assets of Rs. 3457.62 millions as at 31st March 2026, total revenues of 1049.91 millions and Rs. 3539.26 millions, total profit/(loss) after tax Rs. 26.36 millions and Rs. 132.19 millions, total comprehensive income of Rs. 21.78 millions and Rs. 123.73 millions for the quarter and year ended on 31st March 2026



respectively as considered in the Consolidated Financial Results, which have been audited by their respective Independent auditors. The Consolidated Financial Results also includes the audited financial results of five joint ventures and one entity which was an associate for part of the year whose financial statements / financial information reflects Group's share of profit/(loss) of Rs. 1.27 millions and Rs. 20.69 millions for the quarter and year ended on 31<sup>st</sup> March 2026 respectively.

The Independent Auditors' reports on the annual audited financial statements / financial information of these entities have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as relates to the amounts and disclosures included in respect of above entities and our report in terms of sub-section (3) and (11) of section 143 of the Act, insofar as it relates to the aforesaid entities, is based solely on the reports of the other auditors.

Our opinion on the consolidated financial results is not modified in respect of above matter with respect to our reliance on the work done and the reports of such auditors.

2. The Consolidated Financial Results includes the unaudited financial statements / financial information of one subsidiary, whose financial statements / financial information reflect total assets of Rs. 0.5 millions as at 31<sup>st</sup> March 2026, total revenue of Rs. Nil, net profit/(loss) after tax of Rs. Nil and total comprehensive income/(loss) of Rs. Nil for the year ended on 31<sup>st</sup> March 2026, as considered in the Consolidated Financial Results. These financial statement / financial information are unaudited and have been furnished to us by the management and opinion on the consolidated financial results for the year ended 31<sup>st</sup> March, 2026, in so far as it relates to the amounts and disclosures included in respect of the subsidiary is based solely on such unaudited financial statement / financial information. In our opinion and according to the information and explanation given to us by the Board of Directors, these financial statements/ financial information are not material to the group.

Our opinion on the Consolidated Financial Results for the year ended 31<sup>st</sup> March 2026 is not modified in respect of the above matter with respect to our reliance on the financial statements/ financial information certified by the Board of Directors.

3. The accompanying Statement includes the results for the quarter ended 31<sup>st</sup> March, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations. Our opinion on the Audit of the Consolidated Financial Results for the year ended 31<sup>st</sup> March, 2026 is not modified in respect of this matter.

**For SHAH & TAPARIA**  
Chartered Accountants  
FRN: 109463W


**Bharat Joshi**  
Partner

M. No.: 130863

UDIN: 26130863 CZPUJN 8946

Date: May 15, 2026

Place: Mumbai



### Annexure 1

#### List of entities included in consolidated financial results

Name of the Entity	Relationship
Mukka Proteins Limited	Parent Company
Haris Marine Products Private Limited	Wholly Owned Subsidiary Company (Domestic)
Atlantic Marine Products Private Limited	Subsidiary Company (Domestic)
Ocean Aquatic Proteins LLC	Subsidiary Company (Foreign)
Ento Proteins Private Limited	Wholly Owned Subsidiary Company (Domestic)
Fabco Bio Cycle and Bio Protein Technology Private Limited <sup>\$</sup>	Subsidiary Company (Domestic)
Ocean Proteins Private Limited *	Subsidiary Company (Domestic)
United Gulf Fishery Products LLC <sup>\$</sup>	Subsidiary Company (Foreign)
Mukka Frozen Impex <sup>\$</sup>	Subsidiary Entity (Domestic)
MPL HRC Eco Solution LLP <sup>\$</sup>	Subsidiary Entity (Domestic)
Ullal Fish Meal and Oil Company	Joint Venture
GSM Marine Export #	Joint Venture
Progress Frozen and Fish Sterilization	Joint Venture
Pacific Marine Products	Joint Venture
Mangalore Fishmeal and Oil Company	Joint Venture – Indirect

\* Converted from Associate to Subsidiary company during the year.

\$ Newly acquired Subsidiary company during the year.

# Newly acquired joint venture during the year.



**MUKKA PROTEINS LIMITED**  
**CIN: L10207KA2010PLC055771**  
**STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE**  
**QUARTER & YEAR ENDED MARCH 31, 2026**

*Rupees in million, except per share data and if otherwise stated)*

Sr. No.	Particulars	Quarter Ended			Year Ended	
		March 31, 2026	December 31, 2025	March 31, 2025	March 31, 2026	March 31, 2025
		(Audited)	(Un-Audited)	(Audited)	(Audited)	(Audited)
<b>1</b>	<b>Revenue from Operations</b>					
	Revenue from operations	3,679.16	6,346.37	3,722.62	14,035.15	9,800.26
	Other operating income	126.85	188.60	93.09	459.38	263.90
	<b>Total Revenue from operations</b>	<b>3,806.01</b>	<b>6,534.97</b>	<b>3,815.71</b>	<b>14,494.53</b>	<b>10,064.16</b>
<b>2</b>	Other income	151.94	49.33	41.50	286.81	151.15
<b>3</b>	<b>Total income</b>	<b>3,957.95</b>	<b>6,584.30</b>	<b>3,857.21</b>	<b>14,781.35</b>	<b>10,215.31</b>
<b>4</b>	<b>Expenses</b>					
	Cost of Material Consumed	3,754.59	5,819.69	2,545.97	14,307.25	9,161.04
	Changes in inventories of finished goods, stock in trade and work in progress	(750.83)	(310.15)	573.17	(2613.95)	(1414.35)
	Employee benefits expenses	131.30	108.15	85.68	407.75	323.00
	Finance costs	151.70	145.61	103.15	535.96	372.50
	Depreciation and amortisation	51.25	40.30	28.21	165.92	135.51
	Other expenses	332.36	462.86	319.13	1,247.67	1,045.63
	<b>Total expenses</b>	<b>3,670.36</b>	<b>6,266.46</b>	<b>3,655.30</b>	<b>14,050.60</b>	<b>9,623.33</b>
<b>5</b>	<b>Profit before exceptional item, Share of Net Profit / (loss) of Associates and Joint Ventures and tax (3-4)</b>	<b>287.60</b>	<b>317.85</b>	<b>201.90</b>	<b>730.75</b>	<b>591.98</b>
<b>6</b>	<b>Exceptional items</b>	-	-	-	-	-
<b>7</b>	<b>Share of Net Profit / (loss) of Associates and Joint Ventures</b>	1.27	28.35	(0.90)	20.69	10.68
<b>8</b>	<b>Profit before tax (5-6+7)</b>	<b>288.87</b>	<b>346.20</b>	<b>201.01</b>	<b>751.44</b>	<b>602.66</b>
<b>9</b>	<b>Total tax expenses</b>					
	Current Tax	85.70	72.87	50.07	189.82	112.20
	Deferred Tax	(19.30)	0.79	(6.36)	(17.92)	0.09
	Earlier years	8.88	-	17.30	8.67	9.40
<b>10</b>	<b>Profit for the period</b>	<b>213.59</b>	<b>272.53</b>	<b>140.00</b>	<b>570.86</b>	<b>480.97</b>
<b>11</b>	<b>Other Comprehensive Income</b>					
	<u>Items that will not be reclassified subsequently to profit or loss</u>					
	Remeasurement of the net defined benefit plans	2.08	1.90	-1.21	5.19	0.38
	<u>Items that will be reclassified subsequently to profit or loss</u>					
	Exchange differences on translation of foreign operations	(10.76)	8.12	0.44	(11.31)	(3.64)
<b>12</b>	<b>Total other comprehensive income</b>	<b>(8.67)</b>	<b>10.01</b>	<b>(0.76)</b>	<b>(6.12)</b>	<b>(3.26)</b>
<b>13</b>	<b>Total comprehensive income for the period</b>	<b>204.91</b>	<b>282.55</b>	<b>139.23</b>	<b>564.73</b>	<b>477.71</b>
	<b>Profit for the year attributable to:</b>					
	Shareholders of the Company	206.15	237.48	135.85	520.58	464.59
	Non-controlling interests	7.44	35.06	4.14	50.28	16.38
	<b>Other comprehensive income for the year attributable to:</b>					
	Shareholders of the Company	(4.69)	7.01	(0.93)	(1.94)	(1.91)
	Non-controlling interests	(3.98)	3.00	0.16	(4.19)	(1.35)
<b>14</b>	<b>Paid-up equity share capital (Face Value of the share Re. 1/- each) *</b>	300.00	300.00	300.00	300.00	300.00
<b>15</b>	Other equity	-	-	-	4,690.86	4,107.03
<b>16</b>	<b>Earnings per share * (Face Value Rs. 1 /- per share)</b>					
	(a) Basic	0.69	0.79	0.45	1.74	1.55
	(b) Diluted	0.69	0.79	0.45	1.74	1.55

*\*\* Basic & Diluted EPS for all periods, except year ended March 31, 2026 & March 31, 2025, are not annualised.*

*See accompanying notes to the financial results*

**MUKKA PROTEINS LIMITED**  
**CIN: L10809KA2010PLC055771**  
**AUDITED CONSOLIDATED BALANCE SHEET AS AT MARCH 31, 2026**

*(Rupees in million, except per share data and if otherwise stated)*

Particulars	As At	
	31st March 2026	31st March 2025
<b>ASSETS</b>		
<b>Non-Current assets</b>		
Property, Plant and Equipment	1639.21	836.96
Capital Work in Progress	304.73	85.58
Right-of-use Assets	143.49	21.62
Intangible Assets	1.85	0.69
Intangible Assets under development	1.65	-
Goodwill on Consolidation	140.52	67.50
Investment Property	12.19	12.60
Financial Assets		
Investment	558.35	366.64
Loans	1.37	4.37
Other Financial Asset	208.63	18.70
Income Tax Assets	59.29	20.40
Other non-current assets	247.97	70.91
Deferred tax Assets	3.74	-
<b>Total Non-Current Assets</b>	<b>3,322.98</b>	<b>1,505.96</b>
<b>Current assets</b>		
Inventories	8565.53	5642.50
Financial Assets		
Trade Receivables	1818.34	1998.20
Cash and Cash Equivalents	128.81	30.75
Other bank balances	475.48	392.10
Loans	105.15	2.26
Other Financial Assets	170.49	192.70
Other Current Assets	1624.49	998.74
<b>Total Current Assets</b>	<b>12,888.29</b>	<b>9,257.24</b>
<b>Total Assets</b>	<b>16,211.27</b>	<b>10,763.21</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity Share Capital	300.00	300.00
Other Equity	4690.86	4107.03
Non Controlling Interest	296.88	157.98
<b>Total Equity</b>	<b>5,287.75</b>	<b>4,565.01</b>
<b>LIABILITIES</b>		
<b>Non-Current Liabilities</b>		
Financial Liabilities		
Borrowings	321.01	25.21
Lease Liabilities	87.92	16.19
Other Financial Liabilities	-	-
Provisions	23.77	25.53
Deferred Tax Liabilities (Net)	-	25.29
Other Non-Current Liabilities	1.53	1.91
<b>Total Non-Current Liabilities</b>	<b>434.24</b>	<b>94.14</b>
<b>Current Liabilities</b>		
Financial Liabilities		
Borrowings	7356.69	4477.64
Lease Liabilities	27.26	10.04
Trade Payables		
- Due To Micro & Small Enterprises	811.71	330.01
- Due To other than Micro & Small Enterprises	1594.02	1087.97
Other Financial Liabilities	53.37	31.01
Other Current Liabilities	415.44	40.94
Provisions	17.27	13.12
Income Tax Liabilities	213.53	113.33
<b>Total Current Liabilities</b>	<b>10,489.29</b>	<b>6,104.07</b>
<b>Total Equity and Liabilities</b>	<b>16,211.27</b>	<b>10,763.21</b>

**MUKKA PROTEINS LIMITED**  
**CIN: L10207KA2010PLC055771**  
**STATEMENT OF AUDITED CONSOLIDATED CASH FLOW STATEMENT FOR THE**  
**QUARTER & YEAR ENDED MARCH 31, 2026**

*(Rupees in million, except per share data and if otherwise stated)*

Particulars	Year Ended 31st March 2026	Year Ended 31st March 2025
	Rs. In millions	Rs. In millions
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit before tax	751.44	602.66
Adjustment for :		
Depreciation / Amortization	165.92	135.51
Interest Expenses	528.01	262.17
Interest Expenses on Lease Liability & Deposits	7.94	4.00
Interest on Capital & Remuneration from partnership firm	(12.69)	(23.40)
Rent Received	(4.31)	(5.37)
Deferred Subsidy	(0.38)	(0.38)
Interest Income	(42.88)	(27.32)
(Profit)/ Loss on Sale of Fixed Assets	(2.09)	0.23
Share of Profit/Loss of Associate and Joint Venture	(20.69)	(10.68)
	<b>618.83</b>	<b>334.76</b>
<b>Operating profit before working capital changes</b>	<b>1,370.26</b>	<b>937.42</b>
Adjustment for :		
Inventories	(2923.03)	(1409.98)
Trade and Other Receivables	(796.89)	(518.09)
Trade Payables	987.74	55.87
Other Current / Non Current Liabilities	374.12	37.27
Provisions	1.08	8.81
Other Financial liabilities	22.36	(197.70)
	(2334.62)	(2023.83)
<b>Net Cash Generated from Operating activity</b>	<b>(964.35)</b>	<b>(1086.41)</b>
Income Tax Paid	(148.29)	(32.89)
<b>Net Cash from operating activities</b>	<b>(1112.65)</b>	<b>(1119.30)</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of fixed assets / capital works-in-progress	(1205.49)	(200.40)
Capital Advances	(177.06)	(40.67)
Purchase of Investments in Subsidiaries	15.61	(67.50)
Sale proceeds from FA	17.84	16.02
Interest received	42.88	27.32
Interest on Capital & Remuneration Received from firm	12.69	23.40
Share of Profit/Loss of Associate and Joint Venture	20.69	10.68
Rent Received	4.31	5.37
Net (Increase) / Decrease in Investments	(191.30)	(124.08)
<b>Net cash used in investing activities</b>	<b>(1459.83)</b>	<b>(349.86)</b>
<b>C. CASH FLOW FROM FINANCIAL ACTIVITIES</b>		
Net Proceeds from Issue (Net of Share Issue Expenses)	-	(25.27)
Changes in borrowings - Non Current	295.80	(38.71)
Interest Paid	(528.01)	(262.17)
Changes in borrowings - Current	2879.05	918.97
Share in Non Controlling Interest	51.33	20.78
Changes in deeply subordinated loan	13.23	(42.08)
Repayment of Lease Liabilities	(40.86)	(15.99)
<b>Net Cash from financial activities</b>	<b>2,670.55</b>	<b>555.53</b>
<b>INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>98.06</b>	<b>(913.63)</b>
Cash and Cash equivalents at the beginning	30.75	944.38
Cash and Cash equivalents at the close	<b>128.81</b>	<b>30.75</b>

**MUKKA PROTEINS LIMITED**  
**CIN: L10207KA2010PLC055771**  
**NOTES TO THE STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE**  
**QUARTER & YEAR ENDED MARCH 31, 2026**

- 1 The above statement of Audited consolidated financial results for the Quarter & Year Ended March 31, 2026 ('the Statement') of Mukka Proteins Limited ('the Company') are reviewed and recommended by the Audit Committee and taken on record by the Board of Directors at their meeting held on **May 15, 2026**. The Statutory auditors have carried out an audit of the consolidated financial results for the Quarter & Year Ended March 31, 2026 and have issued an unmodified opinion on the same.
- 2 The Audited Consolidated Financial Results of the company are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard Rules), 2015 (as amended) and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended.
- 3 The figures for the quarter ended March 31, 2026 are balancing figure between the audited figures for the year ended March 31, 2026 and published year to date figures for nine months ended December 31, 2025.

The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures for the year ended March 31, 2025 and unaudited figures for the nine months period ended December 31, 2024.

- 4 The Group operates in a single operating segment namely Fish & Insects Protein. The Board of directors is the Chief Operating Decision Maker (the "CODM") of the group and makes operating decisions, assess financials performance & allocate resources based upon discrete financial information. Since the Company operate in a single operating segment, separate segment reporting has not been made under Indian Accounting Standard ("Ind AS") 108 - "Operating Segment". Further, the operation of the Group comprises of geographical segment as disclosed below -

Revenue disaggregation by geography is as

(Rupees in Million)

Particulars	Quarter Ended			Year Ended	
	March 31, 2026	December 31, 2025	March 31, 2025	March 31, 2026	March 31, 2025
	(Audited)	(Un-Audited)	(Audited)	(Audited)	(Audited)
Within India	340.86	1,445.61	773.52	2,853.77	3,047.02
Outside India	3,338.30	4,900.76	2,949.11	11,181.38	6,753.24
<b>Total</b>	<b>3,679.16</b>	<b>6,346.37</b>	<b>3,722.62</b>	<b>14,035.15</b>	<b>9,800.26</b>

**For and on behalf of Board of Directors of**  
**Mukka Proteins Limited**

Date : May 15, 2026  
Place: Mangalore

**Kalandan Mohammed Haris**  
Managing Director and CEO  
DIN: 03020471



## Annexure – I

S. No.	Particulars	Details
1.	Type of securities proposed to be issued (viz. equity shares, convertibles etc.)	Issuance of senior, secured, rated, listed, redeemable, taxable, transferable, INR denominated Non-Convertible Debentures (“ <b>Debentures</b> ”)
2.	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.	Private Placement (through EBP Platform)
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Up to Rs. 25,00,00,000/- (Rupees Twenty-Five Crores only)
4.	Size of the issue	Up to Rs. 25,00,00,000/- (Rupees Twenty-Five Crores only)
5.	Whether proposed to be listed? If yes, name of the stock exchange(s)	Yes, the Debentures are proposed to be listed on Wholesale Debt Market Segment of BSE Limited.
6.	Tenure of the instrument - date of allotment and date of maturity	15 months from Deemed Date of Allotment or such other tenor as may be more particularly set out under the offer document / key information document to be issued in respect of the Debentures.  <b>Date of Allotment:</b> The same shall be set out under the relevant Transaction Documents to be executed in relation to the Debentures.  <b>Date of Maturity:</b> The same shall be set out under the relevant Transaction Documents to be executed in relation to the Debentures.
7.	Coupon/interest offered	12.00% (Twelve Percent) per annum payable every month or such other coupon rate as may be more particularly set out under the offer document / key information document to be issued in respect of the Debentures.
8.	schedule of payment of coupon/interest and principal	The same shall be set out under the relevant Transaction Documents to be executed in relation to the Debentures.
9.	Charge/security, if any, created over the assets	The charge shall be created on the current assets or such other assets of the Company with such raking and security as may be set out under the

### Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India

Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001

☎ : (0) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405

E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771



		relevant Transaction Documents to be executed in relation to the Debentures.
10.	Special right/interest/privileges attached to the instrument and changes thereof	None. The rights/interests/privileges of the holders of the Debentures shall be set out in the debenture trust deed to be entered into between the Company and the debenture trustee in respect of the Debentures, and any other related document thereto (the “ <b>Transaction Documents</b> ”).
11.	Delay in payment of interest / principal amount for a period of more than three months from the due date or default in payment of interest / principal	Yet to be finalized.
12.	Details of any letter or comments regarding payment/non-payment of interest, principal on due dates, or any other matter concerning the security and /or the assets along with its comments thereon, if any	Not Applicable
13.	Details of redemption of debentures indicating the manner of redemption (whether out of profits or out of fresh issue) and debentures	The same shall be set out under the relevant Transaction Documents to be executed in relation to the Debentures.
14.	Any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not Applicable

## Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India

Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001

☎ : (0) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405

E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771



## Annexure – II

S. No.	Particulars	Details
1.	Type of securities proposed to be issued (viz. equity shares, convertibles etc.)	Issuance of senior, secured, rated, listed, redeemable, taxable, transferable, INR denominated Non-Convertible Debentures (“ <b>Debentures</b> ”)
2.	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.	Private Placement (through EBP Platform or non EBP)
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Up to Rs. 50,00,00,000 (Rupees Fifty Crores only) to be raised in one or more tranches / series
4.	Size of the issue	Up to Rs. 50,00,00,000/- (Rupees Fifty Crores only) to be raised in one or more tranches / series
5.	Whether proposed to be listed? If yes, name of the stock exchange(s)	Yes, the Debentures shall be listed on the Wholesale Debt Market Segment of BSE Limited.
6.	Tenure of the instrument - date of allotment and date of maturity	<b>Date of Allotment:</b> The same shall be set out under the relevant Transaction Documents to be executed in relation to the Debentures.  <b>Date of Maturity:</b> The same shall be set out under the relevant Transaction Documents to be executed in relation to the Debentures
7.	Coupon/interest offered	The same shall be set out under the relevant Transaction Documents to be executed in relation to each tranche of the Debentures
8.	schedule of payment of coupon/interest and principal	The same shall be set out under the relevant Transaction Documents to be executed in relation to each tranche of the Debentures.
9.	Charge/security, if any, created over the assets	The same shall be set out under the relevant Transaction Documents to be executed in relation to each tranche of the Debentures.
10.	Special right/interest/privileges attached to the instrument and changes thereof	None. The rights/interests/privileges of the holders of the Debentures shall be set out in the debenture trust deed to be entered into between the Company and the debenture trustee in respect of each tranche of the Debentures, and any other related document thereto (the “ <b>Transaction Documents</b> ”).

### Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India

Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001

☎ : (0) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405

E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771



# Mukka Proteins Limited



ISO 22000  
Certified Company



ISO 9001 : 2015  
Certified Company



11.	Delay in payment of interest / principal amount for a period of more than three months from the due date or default in payment of interest / principal	The same shall be set out under the relevant Transaction Documents to be executed in relation to each tranche of the Debentures
12.	Details of any letter or comments regarding payment/non-payment of interest, principal on due dates, or any other matter concerning the security and /or the assets along with its comments thereon, if any	Not Applicable
13.	Details of redemption of debentures indicating the manner of redemption (whether out of profits or out of fresh issue) and debentures	The same shall be set out under the relevant Transaction Documents to be executed in relation to each tranche of the Debentures
14.	Any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not Applicable

## Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste

**Factory** : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India

**Office** : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001

☎ : (O) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405

E-mail : [info@mukkaproteins.com](mailto:info@mukkaproteins.com) - Website : [www.mukkaproteins.com](http://www.mukkaproteins.com) - CIN : L10207KA2010PLC055771



### Annexure-III

S. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.;	Name of the Target entity: <b>MPL FC HRC JV</b> (under incorporation) Proposed Capital: Rs. 5,00,000/- Turnover: Not applicable (yet to be incorporated)
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	No
3.	Industry to which the entity being incorporated belongs;	Treatment and disposal of animal waste
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The Partnership Firm is proposed to be incorporated for execution of the project pursuant to the work order received by the Company’s Joint Venture for treatment and disposal of animal waste.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
6.	Indicative time period for completion of the acquisition;	31-07-2026
7.	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash
8.	Cost of acquisition and/or the price at which the shares are acquired;	Rs. 2,55,000 (capital contribution by the Company)
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	51% capital contribution and profit-sharing
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	MPL FC HRC JV is proposed to carry on the business of treatment and disposal of animal waste. Line of Business: Treatment and disposal of animal waste. Date of Incorporation: Yet to be incorporated. Turnover of last 3 years: Yet to be incorporated. Country in which the acquired entity has presence: India

### Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India

Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001

☎ : (0) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405

E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771



## Annexure-IV

S. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.;	Name of the Target entity: <b>Lanka Bio Proteins Private Limited</b> (under incorporation) Proposed Capital: Rs. 3,60,00,000/- (approx.) Turnover: Not applicable (yet to be incorporated)
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	No
3.	Industry to which the entity being incorporated belongs;	Manufacturing and trading of marine products and other allied activities.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The proposed investment is being made in order to expand the Company’s international business operations and strengthen its presence in the marine products sector.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	Reporting to Reserve Bank of India under Foreign Exchange Management (Overseas Investment) Regulations, 2022
6.	Indicative time period for completion of the acquisition;	31-12-2026
7.	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash
8.	Cost of acquisition and/or the price at which the shares are acquired;	The Company proposes to invest in and subscribe to the share capital for an amount not exceeding Rs. 2,50,00,000/- equivalent to 9,75,00,000 Sri Lankan Rupee approx. representing <b>49%</b> of the share capital of the proposed entity.
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	The Company proposes to invest in and subscribe to the share capital for an amount not exceeding Rs. 2,50,00,000/- equivalent to 9,75,00,000 Sri Lankan Rupee approx. representing <b>49%</b> of the share capital of the proposed entity.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the	Lanka Bio Proteins Private Limited is proposed to carry on the business of manufacturing and trading of marine products and other allied activities.

### Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India

Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001

☎ : (0) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405

E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771



# Mukka Proteins Limited



ISO 22000  
Certified Company



ISO 9001 : 2015  
Certified Company

acquired entity has presence and any other significant information (in brief);	Line of Business: Manufacturing and trading of marine products and other allied activities. Date of Incorporation: Yet to be incorporated. Turnover of last 3 years: Yet to be incorporated. Country in which the acquired entity has presence: Sri Lanka
--	--

## Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste

**Factory** : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India

**Office** : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001

☎ : (0) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405

E-mail : [info@mukkaproteins.com](mailto:info@mukkaproteins.com) - Website : [www.mukkaproteins.com](http://www.mukkaproteins.com) - CIN : L10207KA2010PLC055771



# Mukka Proteins Limited



ISO 22000  
Certified Company



ISO 9001 : 2015  
Certified Company

Date: 15-05-2026

## National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G  
Bandra Kurla Complex,  
Bandra East, Mumbai-400051  
Scrip Code: MUKKA

## BSE Limited

Listing Department  
Dalal Street,  
Mumbai-400001  
Scrip Code: 544135

Dear Sir/Madam,

### **Subject: Declaration under regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that M/s. Shah & Taparia, Chartered Accountants (FRN-109463W), Statutory Auditors of the Company, have issued the Auditor's Report with unmodified opinion on the audited financial results of the Company (standalone and consolidated) for the financial year ended 31st March 2026.

This is for your information and further dissemination.

Thank you,

For **Mukka Proteins Limited**

**Kalandan Mohammed Althaf**  
Whole-Time Director and CFO

**Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste**

**Factory :** D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India

**Office :** Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001

☎ : (0) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405

E-mail : [info@mukkaproteins.com](mailto:info@mukkaproteins.com) - Website : [www.mukkaproteins.com](http://www.mukkaproteins.com) - CIN : L10207KA2010PLC055771